Tissue processing effects on PD‑L1 biomarker evaluation

This whitepaper examines how different tissue processing workflows can influence the immunohistochemical evaluation of PD‑L1, a key predictive biomarker used to guide immunotherapy decisions. Drawing on a comparative study of multiple tissue processors and PD‑L1 antibody clones, it highlights how processing‑related variables can introduce artifacts, alter staining intensity, and impact result interpretation. The findings underscore the importance of standardized, validated tissue processing to support reliable PD‑L1 assessment and the growing demands of precision and computational pathology.